Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifikafusp alfa + onfekafusp alfa + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Philogen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
**bifikafusp alfa + onfekafusp alfa + pembrolizumab** is a combination therapeutic regimen under investigation primarily for cutaneous T-cell lymphoma, malignant melanoma, and other skin cancers. - **bifikafusp alfa** is a recombinant fusion protein (L19-IL2) comprising the L19 antibody fragment linked to human recombinant interleukin-2, designed to target the extra-domain B of fibronectin on tumor vasculature, delivering immunostimulatory IL-2 directly to the tumor microenvironment. - **onfekafusp alfa** is a recombinant fusion protein (L19-TNF), using the same L19 antibody fragment linked to tumor necrosis factor-alpha, enabling targeted cytotoxicity and vascular disruption within tumors. - **pembrolizumab** is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor on T-cells, blocking immune checkpoint inhibition and promoting anti-tumor T cell activity. The combination leverages tumor-targeted cytokine therapy (by L19-IL2 and L19-TNF) with immune checkpoint inhibition (by pembrolizumab) for a synergistic antitumor immune response, and is currently in Phase II clinical development for cutaneous T-cell lymphoma, with ongoing studies in various skin malignancies[5][8].
- Other names
- bifikafusp alfa + onfekafusp alfaDarleukin + FibromunDarleukin/fibromunDaromunL19-IL2 + L19-TNFL19IL2-L19TNFL-19IL2-L19TNFL 19IL2-L19TNFL19IL2/L19TNFNIDLEGY
02
Targets
ED-B (Fibronectin extra domain B)IL-2R (Interleukin-2/interleukin-15 receptor complex)PDCD1 (Programmed cell death protein 1 receptor)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on bifikafusp alfa + onfekafusp alfa + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifikafusp alfa + onfekafusp alfa + pembrolizumab.